Personalis (PSNL) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Personalis (PSNL) overview

Personalis (PSNL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 69.6m and operating profit of USD -88.1m; the year-end share price was 7.96 USD and market capitalisation was USD 816m. Personalis is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Personalis's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 261mFY 2025
Share price7.96 USDFY 2025 year end
RevenueUSD 69.6mFY 2025
Operating profitUSD -88.1mFY 2025
Net earningsUSD -81.3mFY 2025
Market capitalisationUSD 816mFY 2025 year end

About Personalis

Personalis develops and sells cancer genomic testing services for physicians, pharmaceutical companies, diagnostic companies and population sequencing initiatives. Its tests support detection and monitoring of residual or recurrent cancer, assessment of therapy response, tumor profiling for therapy selection, biomarker discovery and clinical trials. The company also provides whole exome sequencing of cancer samples and whole genome sequencing of human samples.

Generate the Personalis report

Personalis is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Personalis and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Personalis

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.